Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

Shares of California-based Coherus BioSciences (Nasdaq: CHRS) rose more than 5% to $0.88 in pre-market activity today as it ...

India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal ...

The global postpartum depression management market is projected to grow at a steady CAGR of 3.8% over the forecast period from 2022 to 2032. Valued at USD 115.1 million in 2022, the market is expected ...

London-headquartered Accord is one of the largest suppliers of chemotherapy products in Europe and is a wholly-owned subsidiary of India's Intas Pharma, which has annual revenues of around $3.4 ...

Ahmedabad: Intas Pharma has announced the appointment of Parthiv Mehta ... His proven track record in launching new products and building strong brands in these regions will be instrumental in driving ...

EU & Emerging markets post signing the LOI by INTAS Pharmaceuticals as its fully owned subsidiary Sakar Healthcare Limited has informed the Exchange about Certificate under Regulation 74 (5) of the ...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an asset purchase agreement signed by the companies in December 2024 for up ...

Coherus BioSciences (CHRS) announced the completion of the previously announced divestiture of its UDENYCA franchise to Intas Pharmaceuticals ...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an ...

But these same areas are now overcrowded, and price wars are common. Companies like Mankind, Sun Pharma, and Intas are looking at combinations of brand innovation, portfolio reshuffling ...